Recent Efficiency Comparison between Pemetrexed plus Cisplatin and Paclitaxel plus Cisplatin for Advanced Lung Adenocarcinoma_West China Medical Journal

Authors：

 CHENLin , WUQi

Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P. R. China;

Corresponding?author：

Keywords：

Lung adenocarcinoma; Pemetrexed; Paclitaxel; Cisplatin

DOI：

10.7507/1002-0179.20140617

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the recent efficiency and toxicity reactions of pemetrexed plus cisplatin and paclitaxel plus cisplatin for advanced lung adenocarcinoma. Methods One hundred and twenty-four patients with advanced lung adenocarcinoma treated in our hospital between January 2009 and December 2012 were divided into pemetrexed plus cisplatin group (group PP, n=63) and paclitaxel plus cisplatin group (group TP, n=61). The effect was evaluated after two courses of treatment, and the toxicity reactions were evaluated every course. Results The objective response rate, disease control rate and progression-free survival in group PP and TP were respectively 58.7% vs 37.7%, 74.6% vs 52.5%, and 6.1 months vs 4.5 months, with significant differences (P<0.05). The incidence of nausea and vomiting, and white blood cell decrease (neutropenia) in group PP were significantly lower than that in group TP (χ²=16.164, P<0.001; χ²=9.469, P=0.002). There were no significant differences in incidence of thrombocytopenia, anemia and hepatic function damage (χ²=0.098, P=0.755; χ²=0.267, P=0.606; χ²=0.006, P=0.973). Conclusion Pemetrexed plus cisplatin shows obviously superior effects and fewer side effects on advanced lung adenocarcinoma compared with paclitaxel plus cisplatin regime.

Citation： CHENLin, WUQi. Recent Efficiency Comparison between Pemetrexed plus Cisplatin and Paclitaxel plus Cisplatin for Advanced Lung Adenocarcinoma. West China Medical Journal, 2014, 29(11): 2042-2045. doi: 10.7507/1002-0179.20140617 Copy

1.	Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42:157-163.
2.	Kim YH, Kim JS, Choi YH, et al. Phase Ⅱ study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. Int J Clin Oncol, 2002, 7(2):114-119.
3.	Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer[J]. Ther Clin Risk Manag, 2009, 5:781-787.
4.	Cohen MH, Cortazar P, Justice R, et al. Approval summary:pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)[J]. Oncologist, 2010, 15(12):1352-1358.
5.	Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1):122S-150S.
6.	孫燕, 周際昌. 臨床腫瘤內科手冊[M]. 4版. 北京:人民衛生出版社, 2003:97-107.
7.	Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
8.	Rollins KD, Lindley C. Pemetrexed:a multitargeted antifolate[J]. Clin Ther, 2005, 27(9):1343-1382.
9.	Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed:biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mol Cancer Ther, 2007, 6(2):404-417.
10.	張靜, 范繼業, 程艷坤, 等. 培美曲塞二鈉的合成研究進展[J]. 河北化工, 2009, 32(5):5-6, 21.
11.	Standfield L, Weston AR, Barraclough H, et al. Histology as a treatment effect modifier in advanced non-small cell lung cancer:a systematic review of the evidence[J]. Respirology, 2011, 16(8):1210-1220.
12.	姜金, 李倫, 王曉晶, 等. 培美曲塞聯合鉑類對比吉西他濱聯合鉑類治療晚期非小細胞肺癌的meta分析[J]. 中國肺癌雜志, 2011, 14(1):43-48.
13.	Chen M, Shao W, He J, et al. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer[J]. Curr Drug Targets, 2010, 11(1):29-36.
14.	廖日強, 吳一龍. 培美曲塞在肺癌治療中的新進展[J]. 中國處方藥, 2010, 3(3):46-49.
15.	Scagliotti GV, Parikh P, Von Pawel J, et al. PhaseⅢ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21):3543-3551.
16.	Omlin A, D'addario G, Gillessen S, et al. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung[J]. Lung Cancer, 2009, 65(3):383-384.
17.	Ongali B, Hellal F, Rodi D, et al. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier[J]. J Neurotrauma, 2006, 23(5):696-707.
18.	Dogan M, Yalcin B, Utkan G, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer:what is the mechanism?[J]. Lung Cancer, 2009, 66(3):399.

1. Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42:157-163.
2. Kim YH, Kim JS, Choi YH, et al. Phase Ⅱ study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. Int J Clin Oncol, 2002, 7(2):114-119.
3. Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer[J]. Ther Clin Risk Manag, 2009, 5:781-787.
4. Cohen MH, Cortazar P, Justice R, et al. Approval summary:pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)[J]. Oncologist, 2010, 15(12):1352-1358.
5. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1):122S-150S.
6. 孫燕, 周際昌. 臨床腫瘤內科手冊[M]. 4版. 北京:人民衛生出版社, 2003:97-107.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
8. Rollins KD, Lindley C. Pemetrexed:a multitargeted antifolate[J]. Clin Ther, 2005, 27(9):1343-1382.
9. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed:biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mol Cancer Ther, 2007, 6(2):404-417.
10. 張靜, 范繼業, 程艷坤, 等. 培美曲塞二鈉的合成研究進展[J]. 河北化工, 2009, 32(5):5-6, 21.
11. Standfield L, Weston AR, Barraclough H, et al. Histology as a treatment effect modifier in advanced non-small cell lung cancer:a systematic review of the evidence[J]. Respirology, 2011, 16(8):1210-1220.
12. 姜金, 李倫, 王曉晶, 等. 培美曲塞聯合鉑類對比吉西他濱聯合鉑類治療晚期非小細胞肺癌的meta分析[J]. 中國肺癌雜志, 2011, 14(1):43-48.
13. Chen M, Shao W, He J, et al. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer[J]. Curr Drug Targets, 2010, 11(1):29-36.
14. 廖日強, 吳一龍. 培美曲塞在肺癌治療中的新進展[J]. 中國處方藥, 2010, 3(3):46-49.
15. Scagliotti GV, Parikh P, Von Pawel J, et al. PhaseⅢ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21):3543-3551.
16. Omlin A, D'addario G, Gillessen S, et al. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung[J]. Lung Cancer, 2009, 65(3):383-384.
17. Ongali B, Hellal F, Rodi D, et al. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier[J]. J Neurotrauma, 2006, 23(5):696-707.
18. Dogan M, Yalcin B, Utkan G, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer:what is the mechanism?[J]. Lung Cancer, 2009, 66(3):399.

West China Medical Journal

Recent Efficiency Comparison between Pemetrexed plus Cisplatin and Paclitaxel plus Cisplatin for Advanced Lung Adenocarcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content